Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core
[Display omitted] •AXL has been a promising therapeutic target for cancers.•A side-chain ring closure medicinal chemistry approach was conducted.•15c bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core was found to be most potent.•15c exhibited high anti-proliferative activ...
Saved in:
Published in | Bioorganic & medicinal chemistry letters Vol. 29; no. 6; pp. 836 - 838 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
OXFORD
Elsevier Ltd
15.03.2019
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | [Display omitted]
•AXL has been a promising therapeutic target for cancers.•A side-chain ring closure medicinal chemistry approach was conducted.•15c bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core was found to be most potent.•15c exhibited high anti-proliferative activity with IC50 values of 0.3 nM.•15c showed acceptable PK properties with the oral bioavailability of 24.8%.
Starting from the recently launched FLT3/AXL multi-targeted inhibitor Gilteritinib (5), we conducted a side-chain ring closure medicinal chemistry approach leading to the identification of compound 15c as a highly potent AXL inhibitor in the biochemical and cellular anti-proliferative assays, with IC50 values of 1.2 and 0.3 nM, respectively. Compared with the reference compound 5, our new discovered AXL inhibitor 15c is more potent in both assays. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2019.01.018 |